Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, real-world analysis
Số trang: 12
Loại file: pdf
Dung lượng: 2.21 MB
Lượt xem: 8
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Immunotherapy in combination with platinum-etoposide (EP) chemotherapy has been approved as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). However, real-world (RW) data regarding the use of immune checkpoint inhibitors (ICIs) in ES-SCLC are lacking.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Real-world data Small-cell lung cancer PD-1 inhibitor PD-L1 inhibitor First-line treatmentGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 119 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0 -
11 trang 37 0 0
-
13 trang 36 0 0
-
Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image
10 trang 34 0 0 -
Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
9 trang 34 0 0 -
11 trang 33 0 0
-
9 trang 33 0 0
-
CYP4B1 polymorphisms and the risk of breast cancer in Chinese women: A case-control study
14 trang 32 0 0 -
11 trang 32 0 0
-
22 trang 32 0 0
-
16 trang 32 0 0